Study: New antibiotics underprescribed for difficult-to-treat infections
BOSTON — More than 40% of patients with difficult-to-treat pathogens were prescribed older, generic agents despite the FDA approval of several new gram-negative antibiotics, findings showed.According to Sameer S. Kadri-Rodriguez, MD, MS, a staff clinician at the NIH, and colleagues, eight next-generation gram-negative antibiotics have been approved by the FDA since 2014, which include: